吉林长龙药业年报 2023

2023Annual Report CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCKEXCHANGE”) GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higherinvestment risk may be attached than other companies listed on the main board of the Stock Exchange. Prospectiveinvestors should be aware of the potential risks of investing in such companies and should make the decision toinvest only after due and careful consideration. Given that the companies listed on the GEM are generally small and mid-sized companies, there is a risk thatsecurities traded on the GEM may be more susceptible to high market volatility than securities traded on the MainBoard of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded onthe GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any losshowsoever arising from or in reliance upon the whole or any part of the contents of this report. This annual report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited and itssubsidiaries (the “Group” and the “Directors”, respectively) collectively and individually accept full responsibility, includesparticulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange forthe purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirmthat to the best of their knowledge and belief, the information contained in this annual report is accurate and complete in allmaterial respects and not misleading or deceptive, and there are no other matters the omission of which would make anystatement herein or this annual report misleading. GEM GEM GEMGEMGEM GEM 3–4Corporate Information5–7Chairman’s Statement8–15Management Discussion and Analysis16–20Biographical Details of Directors and Senior Management21–29Report of the Directors30–40Corporate Governance Report41Report of the Supervisory Committee42–47Independent Auditor’s Report48Consolidated Statement of Profit or Loss andOther Comprehensive Income49–50Consolidated Statement of Financial Position51Consolidated Statement of Changes in Equity52–53Consolidated Statement of Cash Flows54–123Notes to the Consolidated Financial Statements124Five-Year Financial Summary CORPORATE INFORMATION公司資料 BOARD OF DIRECTORS Executive DirectorsMr. Zhang Hong(Chairman)Mr. Zhang Xiao GuangMr. Zhao Bao GangMr. Wu Guo WenMr. Zhang YiMr. Xu Xiang Fu Independent Non-Executive DirectorsMr. Gao Qi PinMs. Tian JieMr. Bai Jun Gui SUPERVISORSMr. Wang Ying XuMr. Yan Li YuMs. Qiao Xiao Chun COMPLIANCE OFFICERMr. Zhang Hong AUTHORIZED REPRESENTATIVESMr. Zhang HongMr. Zhao Bao Gang AUDITORSPrism Hong Kong and Shanghai LimitedCertified Public AccountantsHong Kong AUDIT COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi Pin REMUNERATION COMMITTEE Mr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Hong CORPORATE INFORMATION公司資料 COMPANY SECRETARY ANDQUALIFIED ACCOUNTANTMr. Mok Sai Cheong Mark,CPA, FCCA CPA, FCCA NOMINATION COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Xiao Guang H H SHARE SHARE REGISTRAR ANDTRANSFER OFFICE 18317M Hong Kong Registrars Limited17M FloorHopewell Centre183 Queen’s Road EastHong Kong PRINCIPAL BANKERIndustrial and Commercial Bank of ChinaHuinan County BranchTonghuaJilin ProvincePRC 625639111101–2 PRINCIPAL PLACE OF BUSINESS IN HONG KONG Room 1101–2, 11/FOffice Tower Two, Grand Plaza625 & 639 Nathan RoadMong Kok, KowloonHong Kong 8049 STOCK CODE8049 31 LEGAL ADDRESS31 Beishan StreetChaoyang TownHuinan CountyTonghuaJilin ProvincePRC http://www.jlchanglong.com WEBSITE ADDRESShttp://www.jlchanglong.com CHAIRMAN’S STATEMENT主席報告 As the Chairman and on behalf of the Board of Directors (the “Board”),I am pleased to present the audited consolidated result of Jilin ProvinceHuinan Changlong Bio-pharmacy Company Limited (the “Company”) andits subsidiaries (collectively referred to as the “Group”) for the year ended31 December 2023. 841,545,000841,586,000193,565,000148,207,00034.5526.45 During the year under review, the total revenue of the Group for theyear ended 31 December 2023 was approximately RMB841,545,000,it’s comparable to last year’s RMB841,586,000. Profit for the yearattributable to owners of the Company decreased to RMB148,207,000from RMB193,565,000 last year. For the year ended 31 December 2023,basic earnings per share decreased to RMB26.45 cents from RMB34.55cents last year. In 2023, the pharmaceutical market was in the backdrop of complexenvironment with the rise of difficulties in sales following the adjustmentof pharmaceutical policy, as well as the intensification of cut-throatmarket competition. All employees of the Company presse